Emergent Biosolutions Inc

NYSE:EBS   3:59:50 PM EDT
+0.43 (+0.92%)

FDA Takes Steps To Increase Availability Of Covid-19 Vaccine

Published: 06/11/2021 15:16 GMT
Emergent Biosolutions Inc (EBS) - FDA Takes Steps to Increase Availability of Covid-19 Vaccine.
FDA Says Authorizing for Use, Under Eua for Janssen Covid-19 Vaccine 2 Batches of Vaccine Drug Substance Manufactured at Emergent Biosolutions Facility in Baltimore.
FDA Says is Taking Steps That Will Allow Supply of the Janssen Covid-19 Vaccine to Be Made Available.
FDA Says It Has Revised the Letter of Authorization for the Janssen Vaccine to Help Facilitate Potential Export to Other Countries.
FDA Says FDA is Not Yet Ready to Include Emergent Biosolutions Plant in the Janssen Eua As an Authorized Manufacturing Facility.
FDA Says FDA Continues to Work Through Issues at Emergent Biosolutions Plant With Janssen and Emergent Biosolutions Management.
FDA Says Under Revised Letter of Authorization, Distribution & Administration of Exported Vaccines Must Comply With Laws of the Recipient Countries.
FDA Says FDA Has Determined Several Other Batches Are Not Suitable for Use, But Additional Batches Are Still Under Review.